61 completed, 9 recruiting, 8 unknown, 6 terminated. 97 Phase 2, 13 Phase 3, 7 Phase 1.
Follow Parathyroid Diseases: new trials by email Literature Review of Parathyroid Diseases trials Research Report on Parathyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenvatinib in Patients With Advanced Parathyroid Carcinoma Lenvatinib - Parathyroid Carcinoma | Phase 2 | Not yet recruiting | Yonsei University | 18 | 2026-11-01 | 2026-09-28 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants CTAP101 - CKD Stage 3, CKD Stage 4 | Phase 2 | Recruiting | OPKO Health, Inc. | 40 | 2026-08-05 | 2026-08-20 |
| Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD Low-dose Colchicine at 0.5mg daily, Usual Care - Chronic Kidney Disease Mineral and Bone Disorder, Hypertension | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-07-01 | 2026-06-22 |
| Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder | Phase 2 | Recruiting | Paul Szabolcs | 25 | 2026-05-04 | 2026-05-15 |
| Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors 18F-FCH, NeuroEXPLORER - Primary Hyperparathyroidism, Parathyroid Cancer | Phase 2 / Phase 3 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 193 | 2026-04-16 | 2026-10-29 |
| A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism Single subcutaneous injection, Multiple subcutaneous injection - Hypoparathyroidism | Phase 2 | Suspended | Peking Union Medical College Hospital | 60 | 2026-04-13 | 2026-09-28 |
| Parathyroid Allotransplant for Treatment of Hypoparathyroidism Parathyroid Allotransplant - Hypoparathyroidism, Hypoparathyroidism Postprocedural | Phase 1 / Phase 2 | Recruiting | Peter Stock | 3 | 2026-01-15 | 2026-02-27 |
| Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism Single subcutaneous injection, Multiple subcutaneous injection - Hypoparathyroidism | Phase 1 / Phase 2 | Suspended | Peking Union Medical College Hospital | 15 | 2025-11-17 | 2026-09-25 |
| Activated Charcoal Use in Chronic Kidney Disease Patients Activated Charcoal, Phosphate Binders - End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis | Phase 2 | Recruiting | Mansoura University | 40 | 2025-08-01 | 2025-08-08 |
| A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism EXT608, Placebo - Hypoparathyroidism | Phase 2 | Recruiting | Extend Biosciences Inc. | 35 | 2025-05-05 | 2025-05-25 |
| Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults AMOR-1, Crystalline Calcium Carbonate - Hypoparathyroidism | Phase 2 | Active not recruiting | Amorphical Ltd. | 62 | 2024-12-15 | 2026-08-14 |
| MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease MT1013, Etelcalcetide Hydrochloride, Placebo - Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | Phase 2 | Completed | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 115 | 2024-11-04 | 2026-07-22 |
| Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection - Hypoparathyroidism | Phase 2 | Active not recruiting | MBX Biosciences | 60 | 2024-10-31 | 2026-10-07 |
| Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Sertraline, Placebo - Neurodevelopmental Disorders, Autism | Phase 2 | Recruiting | Holland Bloorview Kids Rehabilitation Hospital | 130 | 2024-09-16 | 2026-07-27 |
| Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism MBX 2109, Placebo - Hypoparathyroidism | Phase 2 | Completed | MBX Biosciences | 64 | 2024-08-08 | 2026-03-20 |
| The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD Dialysate calcium 1.50 mmol/L - Secondary Hyperparathyroidism, End-stage Kidney Disease | Phase 2 | Unknown | Iain Bressendorff | 48 | 2024-08-01 | 2024-05-03 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia Dexamethasone, Normal saline - Voice Change, Hypocalcemia | Phase 2 | Unknown | Tseung Kwan O Hospital, Hong Kong | 100 | 2024-07-01 | 2024-07-09 |
| Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis MT1013 - Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | Phase 2 | Recruiting | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 310 | 2024-06-07 | 2025-05-16 |
| DePTH: De-emphasize PTH Oral calcitriol with cinacalcet rescue, IV activated vitamin D - Kidney Failure, Chronic, Chronic Kidney Disease-Mineral and Bone Disorder | Phase 2 | Active not recruiting | University of Washington | 90 | 2024-03-11 | 2025-06-02 |
Showing 20 of 97. Sign in to see all of them.
Hyperparathyroidism, Secondary (31) · Hypoparathyroidism (22) · Chronic Kidney Disease-Mineral and Bone Disorder (13) · Hyperparathyroidism (11) · Hyperparathyroidism, Primary (11) · Kidney Failure, Chronic (11) · Renal Insufficiency, Chronic (10) · DiGeorge Syndrome (9) · Parathyroid Neoplasms (9) · Hypocalcemia (7) · Hypercalcemia (6) · 22q11 Deletion Syndrome (3) · Immunologic Deficiency Syndromes (3) · Kidney Diseases (3) · Neoplasm Metastasis (3)
Endocrine System Diseases (96) · Hyperparathyroidism (49) · Pathological Conditions, Signs and Symptoms (35) · Pathologic Processes (32) · Disease Attributes (30) · Female Urogenital Diseases (30) · Female Urogenital Diseases and Pregnancy Complications (30) · Nutritional and Metabolic Diseases (30) · Urogenital Diseases (30) · Chronic Disease (29) · Male Urogenital Diseases (29) · Metabolic Diseases (29) · Urologic Diseases (29) · Calcium Metabolism Disorders (27)
Cinacalcet (17) · Calcitriol (5) · etelcalcetide hydrochloride (5) · Cholecalciferol (4) · Teriparatide (4) · paricalcitol (4) · Standard of Care (3) · Amiloride (2) · Calcium (2) · Denosumab (2) · Drug Implants (2) · Injections, Subcutaneous (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Parathyroid Hormone (2)
Amgen (11) · Abbott (3) · KAI Pharmaceuticals (3) · Kyowa Kirin Co., Ltd. (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · OPKO Health, Inc. (3) · Shaanxi Micot Pharmaceutical Technology Co., Ltd. (3) · Sumitomo Pharma Switzerland GmbH (3) · Amorphical Ltd. (2) · Columbia University (2) · Deltanoid Pharmaceuticals (2) · Entera Bio Ltd. (2) · Iain Bressendorff (2) · MBX Biosciences (2) · National Center for Research Resources (NCRR) (2)
United States (44) · China (10) · Japan (8) · Italy (7) · Canada (6) · Denmark (4) · France (4) · Israel (4) · Argentina (3) · Poland (3) · Turkey (Türkiye) (3) · Belgium (2) · Czechia (2) · Germany (2) · Hungary (2)
M. Louise Markert, MD, PhD (3) · Thomas Nickolas, MD, MS (3) · Joel Melnick, MD (2) · Karen K Winer, M.D. (2) · M D (2) · Ravi Thadhani, MD (2) · Smita Jha, M.D. (2) · Xueqing Yu, MD (2) · Yan Qin (2) · Agnes Linglart, MD, PhD (1) · Anand Vaidya, MD MMSc (1) · Andrei Iagaru, MD (1) · Anne Blanchard, MD, PhD (1) · Arthur Santora, MD (1)
PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 17284531, PMID 40576086, PMID 12702512, PMID 15522938, PMID 15983958, PMID 17699221, PMID 18155964, PMID 18310602, PMID 18397701, PMID 19776051, PMID 19837909, PMID 20943783, PMID 20978268, PMID 21565561, PMID 22090268, PMID 22118402, PMID 23222688, PMID 23607606, PMID 23914737, PMID 23990665, PMID 24687385, PMID 24948345, PMID 25955226, PMID 27880946, PMID 29270788, PMID 29972871, PMID 31599480, PMID 31969335, PMID 32582855, PMID 33283264, PMID 33362722, PMID 33882143, PMID 34347093, PMID 34380663, PMID 34716198, PMID 35018442, PMID 35176038, PMID 36271471, PMID 36512619, PMID 37574661, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692
K12HD043494 (3), R01AI047040 (3), R01AI054843 (3), R56AI047040 (2), 2008 (1), 2009 (1), 2016 (1), K23DK136930 (1), M01RR000042 (1), R01DK069350 (1), R01DK084986 (1), R44DK138647 (1), U10CA180888 (1)